Related Experiment Video
Updated: Jun 8, 2025
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.2K
The Optimal Radiotherapy Strategy for Patients With Small Cell Lung Cancer and Brain Metastasis: A Retrospective
Qian Zeng1, Xianjing Chu1, Gang Xiao1
1Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
CNS Neuroscience & Therapeutics
|November 5, 2024
Summary
For extensive-stage small cell lung cancer (ES-SCLC) patients receiving immunotherapy, thoracic radiotherapy (TRT) improves survival. Brain radiotherapy (BRT) benefits overall survival, especially when given after immunotherapy, but not if TRT was previously administered.
Area of Science:
- Oncology
- Radiotherapy
- Immunotherapy
Background:
- Extensive-stage small cell lung cancer (ES-SCLC) is aggressive and often involves brain metastases (BMs).
- Treatment challenges persist for ES-SCLC, particularly with BMs.
- The efficacy of combining immunotherapy with radiotherapy, specifically brain radiotherapy (BRT), requires further investigation in the current treatment era.
Purpose of the Study:
- To evaluate the impact of immunotherapy combined with various radiotherapy techniques on survival outcomes in ES-SCLC patients.
- To specifically assess the influence of brain radiotherapy (BRT) on overall survival (OS) and progression-free survival (PFS) in the context of immune checkpoint inhibitors (ICIs).
- To explore the role of thoracic radiotherapy (TRT) and the sequencing of BRT with ICIs.
Main Methods:
- Retrospective analysis of 393 ES-SCLC patients treated with immune checkpoint inhibitors (ICIs) between February 2020 and June 2024.
- Evaluation of overall survival (OS) and progression-free survival (PFS) as primary endpoints.
- Application of univariate and multivariate Cox regression models to identify prognostic factors.
Main Results:
- Thoracic radiotherapy (TRT) was a significant positive prognostic factor for both OS and PFS.
- Brain radiotherapy (BRT) improved OS in the overall cohort and in patients with baseline BMs.
- Combining ICIs with BRT did not improve OS in patients with baseline BMs who had prior TRT, but it did improve OS in those without prior TRT.
- Administering BRT before ICIs (RT-ICI) was associated with worse PFS compared to ICI-RT.
- For patients without baseline BMs, TRT and prophylactic cranial irradiation were linked to a delayed onset of BMs.
Conclusions:
- Optimizing treatment strategies by integrating radiotherapy and immunotherapy is crucial for improving outcomes in ES-SCLC.
- The timing of BRT relative to ICIs significantly impacts PFS.
- TRT is a favorable prognostic factor, and prophylactic cranial irradiation may delay BMs in select patients.
